In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. Attainable new approaches to the prognosis and treatment of AML. (A) The identification https://elizabethc444tfu9.theblogfairy.com/profile